Imprimis Pharmaceuticals Inc. (IMMY) Shares Up 5.1%
Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY)’s share price shot up 5.1% on Friday . The stock traded as high as $3.69 and last traded at $3.69, with a volume of 96,374 shares traded. The stock had previously closed at $3.51.
Separately, Zacks Investment Research downgraded shares of Imprimis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 20th.
The firm’s market capitalization is $49.11 million. The firm has a 50-day moving average of $3.86 and a 200-day moving average of $4.38.
Imprimis Pharmaceuticals (NASDAQ:IMMY) last released its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.27) by $0.16. The firm had revenue of $4.40 million for the quarter, compared to analysts’ expectations of $3.24 million. Analysts expect that Imprimis Pharmaceuticals Inc. will post ($0.94) EPS for the current fiscal year.
Imprimis Pharmaceuticals, Inc (Imprimis) is a pharmaceutical company. The Company focuses on developing and commercializing compounded drug therapies and making these therapies available to physicians and patients. It owns, markets and sells a portfolio of combination formulations in ophthalmology and urology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.